It is a beacon of hope for many terminally ill cancer patients. Researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust in London, UK, found that the combination of two immunotherapy drugs could reduce the size of tumors in terminally ill patients certain cancers, in particular that of the brain and throat.
Relayed by The Guardian, the study states that the combination of these two drugs, namely nivolumab and ipilimumab, leads to a considerable reduction in the size of tumors in end-stage cancer patients. In some cases, the tumors have completely disappeared and the patients have recovered.
These results are very promising, say the researchers who say that this treatment caused much fewer side effects than chemotherapy, the standard treatment offered to many patients with advanced cancer. “Immunotherapies are smarter, gentler treatments that can provide significant benefits to patients,” ICR CEO Professor Kristian Helin told The Guardian.
It should be noted that in the context of this trial, the data of nearly 1000 patients with brain and throat cancer were analyzed. Similar results have also been observed in patients with terminal cancer of the kidneys, skin and intestines, according to the same source.